PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION

Sans, T. ; Joven, J. ; Vilella, E. ; Masdeu, G. ; Farrè, M.

Oxford, UK : Blackwell Publishing Ltd
Published 2000
ISSN:
1440-1681
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
〈list xml:id="l1" style="custom"〉1The aim of the present study was to assess the effectiveness of repeated subcutaneous low-dose recombinant human erythropoietin (rHuEPO) on parameters associated with improved procurement of autologous blood; a procedure regularly used to preclude the need for homologous blood transfusion at the time of elective surgery.2Three groups of three volunteers each (n= 9) were administered one of three low doses of rHuEPO (30, 60 or 100 IU/kg body weight, s.c.) on days 1,4 and 8. The plasma pharmacokinetic profile of rHuEPO was studied after the first and third injections. Statistical evaluations were intragroup and intra-individual comparisons.3There was a linear relationship between maximum plasma concentration (Cmax) and dose. In the overall study group, Cmax and area under the curve (AUC) were significantly decreased, while the mean residence time (MRT) and elimination half-life (t1/2β) were significantly increased on day 8 relative to day 1. Significant and sustained increases in reticulocytes were observed after rHuEPO administration, which were maintained above the predose values throughout the study period.4In conclusion, rHuEPO, by subcutaneous repeat-dose, was eliminated more slowly and remained longer in the circulation, despite lowered plasma concentrations. Repeated low rHuEPO administration at doses ≥ 60 IU/kg bodyweight stimulated modest but sustained reticulocyte concentrations, suggesting that cost may be substantially decreased in autologous blood donation or perioperative treatment programmes.
Type of Medium:
Electronic Resource
URL:
_version_ 1798290147951771649
autor Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
autorsonst Masdeu, G.
Farrè, M.
book_url http://dx.doi.org/10.1111/j.1440-1681.2000.tb03078.x
datenlieferant nat_lic_papers
hauptsatz hsatz_simple
identnr NLZ242575994
insertion_date 2012-04-27
issn 1440-1681
journal_name Clinical and experimental pharmacology and physiology
materialart 1
notes 〈list xml:id="l1" style="custom"〉1The aim of the present study was to assess the effectiveness of repeated subcutaneous low-dose recombinant human erythropoietin (rHuEPO) on parameters associated with improved procurement of autologous blood; a procedure regularly used to preclude the need for homologous blood transfusion at the time of elective surgery.2Three groups of three volunteers each (n= 9) were administered one of three low doses of rHuEPO (30, 60 or 100 IU/kg body weight, s.c.) on days 1,4 and 8. The plasma pharmacokinetic profile of rHuEPO was studied after the first and third injections. Statistical evaluations were intragroup and intra-individual comparisons.3There was a linear relationship between maximum plasma concentration (Cmax) and dose. In the overall study group, Cmax and area under the curve (AUC) were significantly decreased, while the mean residence time (MRT) and elimination half-life (t1/2β) were significantly increased on day 8 relative to day 1. Significant and sustained increases in reticulocytes were observed after rHuEPO administration, which were maintained above the predose values throughout the study period.4In conclusion, rHuEPO, by subcutaneous repeat-dose, was eliminated more slowly and remained longer in the circulation, despite lowered plasma concentrations. Repeated low rHuEPO administration at doses ≥ 60 IU/kg bodyweight stimulated modest but sustained reticulocyte concentrations, suggesting that cost may be substantially decreased in autologous blood donation or perioperative treatment programmes.
package_name Blackwell Publishing
publikationsjahr_anzeige 2000
publikationsjahr_facette 2000
publikationsjahr_intervall 7999:2000-2004
publikationsjahr_sort 2000
publikationsort Oxford, UK
publisher Blackwell Publishing Ltd
reference 27 (2000), S. 0
search_space articles
shingle_author_1 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
shingle_author_2 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
shingle_author_3 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
shingle_author_4 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
shingle_catch_all_1 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
Blackwell Publishing Ltd
〈list xml:id="l1" style="custom"〉1The aim of the present study was to assess the effectiveness of repeated subcutaneous low-dose recombinant human erythropoietin (rHuEPO) on parameters associated with improved procurement of autologous blood; a procedure regularly used to preclude the need for homologous blood transfusion at the time of elective surgery.2Three groups of three volunteers each (n= 9) were administered one of three low doses of rHuEPO (30, 60 or 100 IU/kg body weight, s.c.) on days 1,4 and 8. The plasma pharmacokinetic profile of rHuEPO was studied after the first and third injections. Statistical evaluations were intragroup and intra-individual comparisons.3There was a linear relationship between maximum plasma concentration (Cmax) and dose. In the overall study group, Cmax and area under the curve (AUC) were significantly decreased, while the mean residence time (MRT) and elimination half-life (t1/2β) were significantly increased on day 8 relative to day 1. Significant and sustained increases in reticulocytes were observed after rHuEPO administration, which were maintained above the predose values throughout the study period.4In conclusion, rHuEPO, by subcutaneous repeat-dose, was eliminated more slowly and remained longer in the circulation, despite lowered plasma concentrations. Repeated low rHuEPO administration at doses ≥ 60 IU/kg bodyweight stimulated modest but sustained reticulocyte concentrations, suggesting that cost may be substantially decreased in autologous blood donation or perioperative treatment programmes.
1440-1681
14401681
shingle_catch_all_2 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
Blackwell Publishing Ltd
〈list xml:id="l1" style="custom"〉1The aim of the present study was to assess the effectiveness of repeated subcutaneous low-dose recombinant human erythropoietin (rHuEPO) on parameters associated with improved procurement of autologous blood; a procedure regularly used to preclude the need for homologous blood transfusion at the time of elective surgery.2Three groups of three volunteers each (n= 9) were administered one of three low doses of rHuEPO (30, 60 or 100 IU/kg body weight, s.c.) on days 1,4 and 8. The plasma pharmacokinetic profile of rHuEPO was studied after the first and third injections. Statistical evaluations were intragroup and intra-individual comparisons.3There was a linear relationship between maximum plasma concentration (Cmax) and dose. In the overall study group, Cmax and area under the curve (AUC) were significantly decreased, while the mean residence time (MRT) and elimination half-life (t1/2β) were significantly increased on day 8 relative to day 1. Significant and sustained increases in reticulocytes were observed after rHuEPO administration, which were maintained above the predose values throughout the study period.4In conclusion, rHuEPO, by subcutaneous repeat-dose, was eliminated more slowly and remained longer in the circulation, despite lowered plasma concentrations. Repeated low rHuEPO administration at doses ≥ 60 IU/kg bodyweight stimulated modest but sustained reticulocyte concentrations, suggesting that cost may be substantially decreased in autologous blood donation or perioperative treatment programmes.
1440-1681
14401681
shingle_catch_all_3 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
Blackwell Publishing Ltd
〈list xml:id="l1" style="custom"〉1The aim of the present study was to assess the effectiveness of repeated subcutaneous low-dose recombinant human erythropoietin (rHuEPO) on parameters associated with improved procurement of autologous blood; a procedure regularly used to preclude the need for homologous blood transfusion at the time of elective surgery.2Three groups of three volunteers each (n= 9) were administered one of three low doses of rHuEPO (30, 60 or 100 IU/kg body weight, s.c.) on days 1,4 and 8. The plasma pharmacokinetic profile of rHuEPO was studied after the first and third injections. Statistical evaluations were intragroup and intra-individual comparisons.3There was a linear relationship between maximum plasma concentration (Cmax) and dose. In the overall study group, Cmax and area under the curve (AUC) were significantly decreased, while the mean residence time (MRT) and elimination half-life (t1/2β) were significantly increased on day 8 relative to day 1. Significant and sustained increases in reticulocytes were observed after rHuEPO administration, which were maintained above the predose values throughout the study period.4In conclusion, rHuEPO, by subcutaneous repeat-dose, was eliminated more slowly and remained longer in the circulation, despite lowered plasma concentrations. Repeated low rHuEPO administration at doses ≥ 60 IU/kg bodyweight stimulated modest but sustained reticulocyte concentrations, suggesting that cost may be substantially decreased in autologous blood donation or perioperative treatment programmes.
1440-1681
14401681
shingle_catch_all_4 Sans, T.
Joven, J.
Vilella, E.
Masdeu, G.
Farrè, M.
PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
Blackwell Publishing Ltd
〈list xml:id="l1" style="custom"〉1The aim of the present study was to assess the effectiveness of repeated subcutaneous low-dose recombinant human erythropoietin (rHuEPO) on parameters associated with improved procurement of autologous blood; a procedure regularly used to preclude the need for homologous blood transfusion at the time of elective surgery.2Three groups of three volunteers each (n= 9) were administered one of three low doses of rHuEPO (30, 60 or 100 IU/kg body weight, s.c.) on days 1,4 and 8. The plasma pharmacokinetic profile of rHuEPO was studied after the first and third injections. Statistical evaluations were intragroup and intra-individual comparisons.3There was a linear relationship between maximum plasma concentration (Cmax) and dose. In the overall study group, Cmax and area under the curve (AUC) were significantly decreased, while the mean residence time (MRT) and elimination half-life (t1/2β) were significantly increased on day 8 relative to day 1. Significant and sustained increases in reticulocytes were observed after rHuEPO administration, which were maintained above the predose values throughout the study period.4In conclusion, rHuEPO, by subcutaneous repeat-dose, was eliminated more slowly and remained longer in the circulation, despite lowered plasma concentrations. Repeated low rHuEPO administration at doses ≥ 60 IU/kg bodyweight stimulated modest but sustained reticulocyte concentrations, suggesting that cost may be substantially decreased in autologous blood donation or perioperative treatment programmes.
1440-1681
14401681
shingle_title_1 PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
shingle_title_2 PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
shingle_title_3 PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
shingle_title_4 PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
sigel_instance_filter dkfz
geomar
wilbert
ipn
albert
source_archive Blackwell Publishing Journal Backfiles 1879-2005
timestamp 2024-05-06T08:12:06.795Z
titel PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
titel_suche PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION
topic WW-YZ
uid nat_lic_papers_NLZ242575994